AIM
ESPR

Alambic Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Alambic Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,707
Closed -$442K – 479
2017
Q4 		$442K Sell
6,707
-3,400
-34% -$183K 0.05% 331
2017
Q3 		$507K Buy
10,107
+2,200
+28% +$106K 0.06% 346
2017
Q2 		$366K Sell
7,907
-2,000
-20% -$73.5K 0.04% 428
2017
Q1 		$350K Buy
+9,907
New +$227K 0.04% 473

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alambic Investment Management's ESPR Position: Q1 2018 in Review

Alambic Investment Management sold out of Esperion Therapeutics (ESPR) in Q1 2018, closing a stake of 6,707 shares — an estimated $442K sold.

Alambic Investment Management first reported a position in ESPR in Q1 2017 and held it in 4 quarters. The position peaked at $507K in Q3 2017. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

  • Alambic Investment Management reported no remaining Esperion Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Alambic Investment Management sold 6,707 Esperion Therapeutics shares in Q1 2018, an estimated $442K.
  • Alambic Investment Management first reported a position in Esperion Therapeutics in Q1 2017 and held it in 4 quarters.
  • Alambic Investment Management's Esperion Therapeutics position peaked at $507K in Q3 2017.
  • 187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Alambic Investment Management's 13F filing for Q1 2018, filed 8 May 2018.